Eton Pharmaceuticals, Inc.
ETON · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $39 | $32 | $21 | $22 |
| % Growth | 23.3% | 48.9% | -2.7% | – |
| Cost of Goods Sold | $16 | $11 | $7 | $3 |
| Gross Profit | $23 | $21 | $14 | $19 |
| % Margin | 60% | 66.6% | 67.4% | 88% |
| R&D Expenses | $3 | $3 | $4 | $6 |
| G&A Expenses | $23 | $19 | $19 | $14 |
| SG&A Expenses | $23 | $19 | $19 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26 | $22 | $23 | $21 |
| Operating Income | -$3 | -$1 | -$8 | -$1 |
| % Margin | -6.7% | -3.8% | -38.9% | -6.8% |
| Other Income/Exp. Net | -$1 | $1 | -$1 | -$0 |
| Pre-Tax Income | -$4 | -$1 | -$9 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$1 | -$9 | -$2 |
| % Margin | -9.8% | -3% | -42.4% | -9% |
| EPS | -0.15 | -0.037 | -0.36 | -0.078 |
| % Growth | -311% | 89.9% | -363.9% | – |
| EPS Diluted | -0.15 | -0.037 | -0.36 | -0.078 |
| Weighted Avg Shares Out | 26 | 26 | 25 | 25 |
| Weighted Avg Shares Out Dil | 26 | 26 | 25 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $2 | $0 |
| EBITDA | -$1 | -$0 | -$6 | -$1 |
| % Margin | -3.7% | -0.9% | -30.5% | -4.7% |